September 1, 2020
Sanofi’s anti-CD38 antibody Sarclisa (isatuximab) was launched in Japan on August 31 for the treatment of relapsed/refractory multiple myeloma following its NHI price listing earlier in the month. Sarclisa is a monoclonal antibody that targets a specific epitope on the...read more